• Liujia He, Jiangfeng Li, Xiao Wang, Yufan Ying, Haiyun Xie, Huaqing Yan, Xiangyi Zheng, and Liping Xie.
• Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
• J. Cell. Mol. Med. 2018 Oct 1; 22 (10): 4630-4639.

AbstractAs the most abundant and reversible RNA modification in eukaryotic cells, m6 A triggers a new layer of epi-transcription. M6 A modification occurs through a methylation process modified by "writers" complexes, reversed by "erasers", and exerts its role depending on various "readers". Emerging evidence shows that there is a strong association between m6 A and human diseases, especially cancers. Herein, we review bi-aspects of m6 A in regulating cancers mediated by the m6 A-associated proteins, which exert vital and specific roles in the development of various cancers. Generally, the m6 A modification performs promotion or inhibition functions (dual role) in tumorigenesis and progression of various cancers, which suggests a new concept in cancer regulations. In addition, m6 A-targeted therapies including competitive antagonists of m6 A-associated proteins may provide a new tumour intervention in the future.© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

40 keywords...

hide…